本报告中的患者是一名 73 岁男性，通过 X 光检查在肺右下叶发现一个 5.5 厘米的肿瘤，后被诊断为小细胞肺癌（T3N0M0 IIB 期）。右下肺叶切除及淋巴结清扫术后，术后给予顺铂和依托泊苷辅助化疗。术后27个月，患者主诉喘息。通过计算机断层扫描和支气管镜检查发现气管转移。活检证实小细胞肺癌转移。对纵隔淋巴结（包括锁骨上区域）进行放射治疗（60Gy）。然后，患者接受了四个周期的卡铂-依托泊苷-durvalumab 治疗，然后进行 durvalumab 维持治疗。术后49个月，患者主诉说话时有不适，导致声门下间隙发现结节，证实小细胞肺癌转移。对喉部和纵隔进行放射治疗（30Gy），患者继续接受 durvalumab 单药治疗。截至术后 61 个月，第二个疗程的放疗后，他仍然没有复发。我们良好的结果可以通过免疫疗法和放射疗法之间的协同作用来解释。在这里，我们报告了一个罕见的小细胞肺癌术后气管转移病例，通过放疗和度瓦鲁单抗成功治疗。这显示出实现局部疾病控制和延长术后转移灶生存率的希望，凸显了一种潜在的治疗方法。© 2023 作者。中国肺肿瘤学组与John Wiley联合出版《胸癌》

The patient in this report was a 73-year-old male who was diagnosed with small cell lung cancer (T3N0M0 stage IIB) after presenting with a 5.5 cm tumor detected in the right lower lobe of the lung by radiography. After right lower lobectomy and lymphadenectomy, postoperative adjuvant chemotherapy was administered with cisplatin and etoposide. At 27 months after surgery, the patient complained of wheezing. Tracheal metastasis was identified through computed tomography and bronchoscopy. Biopsy confirmed metastasis of small cell lung cancer. Radiotherapy (60 Gy) was administered to the mediastinal lymph nodes, including the supraclavicular region. The patient then underwent four cycles of carboplatin-etoposide-durvalumab, followed by durvalumab maintenance therapy. At 49 months after surgery, the patient complained of discomfort while speaking, leading to the discovery of a nodule in the subglottic space, which confirmed small cell lung cancer metastasis. Radiotherapy (30 Gy) was administered to the larynx and mediastinum, and the patient continued with durvalumab monotherapy. As of 61 months after surgery, he remains recurrence-free after the second course of radiotherapy. Our favorable outcome could be explained by the synergy between immunotherapy and radiotherapy. Here, we report a rare case of postoperative tracheal metastasis in small cell lung cancer successfully managed with radiotherapy and durvalumab. This shows promise in achieving local disease control and extending survival in postoperative metastatic lesions, highlighting a potential therapeutic approach.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.